Pfiz­er de­tails re­sults from failed Phase 3 tri­al of Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py 

The full re­sults from Pfiz­er’s piv­otal study of its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py show pa­tients saw no sig­nif­i­cant func­tion­al ben­e­fit one year af­ter re­ceiv­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER